Bax R P, Bastain W, Featherstone A, Wilkinson D M, Hutchison M, Haworth S J
ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
J Antimicrob Chemother. 1989 Sep;24 Suppl A:311-20. doi: 10.1093/jac/24.suppl_a.311.
Two human volunteer studies were performed with meropenem: a dose proportionality study of 0.25, 0.5 and 1.0 g and a probenecid interaction study. Six volunteers took part in each study. Meropenem was generally well tolerated: One volunteer was withdrawn from the dose proportionality study because of looseness of stool and abdominal pain after a dose of 1.0 g. The plasma concentrations of meropenem were linearly related to dose. The half-life of meropenem was approximately 1 h and the urinary recovery of unchanged drug was 79%. In the presence of probenecid the plasma half-life of meropenem was increased by 33% but the urinary recovery was unaffected.